Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID (ALLAY-LID-II)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02153632 |
|
Recruitment Status :
Terminated
First Posted : June 3, 2014
Results First Posted : April 2, 2019
Last Update Posted : April 12, 2019
|
Sponsor:
Osmotica Pharmaceutical US LLC
Information provided by (Responsible Party):
Osmotica Pharmaceutical US LLC
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Parkinson's Disease Levodopa Induced Dyskinesia (LID) | Drug: amantadine HCl ER Drug: Placebo | Phase 3 |
This study was terminated early due to slow enrollment with 135 of 162 planned subjects enrolled. Amantadine HCl ER has been used for many years as a treatment for Parkinson's disease. It has been reported in the literature to effectively treat the motor complications of levodopa, especially dyskinesia, but it must be given 2 to 4 times a day. The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease. The dose will be given once a day in the morning so that amantadine concentrations are maintained throughout the day for treating the levodopa induced dyskinesia, but will be lower during the night, potentially reducing the negative impact of amantadine on sleep.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 135 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias |
| Actual Study Start Date : | July 30, 2014 |
| Actual Primary Completion Date : | May 20, 2016 |
| Actual Study Completion Date : | May 20, 2016 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Parkinson disease
MedlinePlus related topics:
Parkinson's Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 240mg amantadine HCl ER tablets
amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
|
Drug: amantadine HCl ER
Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
Other Name: Osmolex ER Tablet |
|
Experimental: 320mg amantadine HCl ER tablets
amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
|
Drug: amantadine HCl ER
Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
Other Name: Osmolex ER Tablet |
|
Placebo Comparator: Placebo Tablets for Amantadine
Placebo, tablets, once daily, 26 weeks.
|
Drug: Placebo
subjects are given an identical placebo tablet
Other Name: Placebo tablets |
Primary Outcome Measures :
- Unified Dyskinesia Rating Scale [ Time Frame: Change from baseline to Day 98 ]The Unified Dyskinesia Rating Scale is a validated tool for assessment of dyskinesia (involuntary movements) in Parkinson's Disease patients. Rating consists of the change from baseline to Day 98 of the sum of the 26 questions comprising the questionnaire. Each question in the questionnaire is rated on a 5 point scale from 0-4 where 0 is a better outcome. Questions assess: over the past week total hours with dyskinesia and total hours without dyskinesia; problems with speech, chewing and swallowing, eating, dressing, hygiene, handwriting, hobbies, balance, socializing, emotions, spasm or cramps, pain without dystonia and pain from dystonia. The minimum (better) value is 0 and the maximum (worse) value is 130.
Secondary Outcome Measures :
- Mobility State Self-Assessment - Subject Diary Cards [ Time Frame: Day 14 and Day 98 of treatment ]hange from baseline in the number of awake hours without troublesome dyskinesia (involuntary movements). Every half hour the subject will indicate in the diary if the medication has ("ON") or has not ("OFF") produced benefits in terms of mobility, slowness and rigidity. Valid diaries of the 3 consecutive days prior to each visit will be averaged with respect to the number of awake hours without troublesome dyskinesia. The change from baseline in the number of waking hours that subjects report being "ON" without troublesome dyskinesias will be analyzed at analysis visits Day 14 and Day 98 of treatment. Higher scores mean a better outcome and the maximum value is 24 hours.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 30 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) informed consent form.
- Idiopathic Parkinson's disease per the United Kingdom (UK) Parkinson's Disease Society Brain Bank criteria.
- Male or female 30 to 85 years old.
- Levodopa induced, predictable peak-effect dyskinesia considered problematic and/or disabling.
- Screening serum creatinine level within normal range
- On stable doses of all oral anti-Parkinson's medication, including any levodopa preparation, for 30 days and be willing to remain on the same doses throughout the trial.
- The subject/caregiver must demonstrate the ability to complete an accurate home diary based on training and evaluation during the screening period.
Exclusion Criteria:
- Secondary parkinsonian syndrome, such as vascular, postinflammatory,drug-induced, neoplastic and post-traumatic parkinsonism or any atypical parkinsonian syndrome (e.g., Progressive Supranuclear Palsy, Multi-System Atrophy, etc.);
- Use of amantadine within 14 days before study start, or previously had an adverse event to amantadine
- Currently taking neuroleptics and atypical antipsychotic agents, acetylcholinesterase inhibitors, apomorphine, rimantadine, memantine and dextromethorphan and quinidine if used in combination for treating dyskinesia.
- History of neurosurgical intervention for treating Parkinson's s disease (i.e. pallidotomy or implanted with a deep brain stimulator)
- Any medical condition or past medical history that would increase the risk of exposure to Amantadine HCl Extended Release Tablets or interfere with safety and efficacy evaluations.
- History of cancer within 5 years of screening with following exceptions: adequately treated non-melanomatous skin cancers, localized bladder cancer, non-metastatic prostate cancer or in situ cervical cancer.
- History or current diagnosis of schizophrenia or bipolar disorder;
- Inadequately treated Major Depressive Disorder. Subjects on stable doses of selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) are eligible for the study;
- Is at imminent risk of suicide or had a suicide attempt within 6 months of screening
- History or current diagnosis of Impulse Control Disorder
- Calculated plasma creatinine clearance of <60 mL/min at screening
- History of or currently has any of the following clinically significant conditions, cardiovascular, respiratory, renal, hepatic, or gastrointestinal disease
- Any clinically significant vital sign, ECG, or laboratory abnormalities;
- A positive test for HIV antibody or history of HIV; hepatitis B surface antigen unless the positive test followed a recent (<28 days) vaccination for hepatitis B; hepatitis C antibody;
- A positive urine drug test.
- Pregnant or breastfeeding at screening or has a positive pregnancy test
- If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize an effective method of contraception from the screening visit to at least 4 weeks after the completion of study treatment.
- History of alcohol or narcotic substance abuse ≤1 year before screening.
- Has dementia or another psychiatric illness that prevents provision of informed consent.
- Has a known hypersensitivity to the study treatment(s), based on known allergies to drugs of the same class including rimantadine HCl and memantine HCl.
- Has participated in other studies involving investigational drugs or surgeries within the last 30 days or investigational biologics within the last 6 months prior to screening.
- Plans to undergo major elective surgery during the course of the study.
- Received administration of Live Attenuated Influenza Vaccine (LAIV) within 2 weeks.
- Cognitive impairment, as evidenced by a score <26 on the Montreal Cognitive Assessment (MoCA) at the screening visit.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02153632
Locations
Show 56 study locations
Sponsors and Collaborators
Osmotica Pharmaceutical US LLC
Investigators
| Study Chair: | Angela Dentiste, MBA | Osmotica Pharmaceutical US LLC |
| Responsible Party: | Osmotica Pharmaceutical US LLC |
| ClinicalTrials.gov Identifier: | NCT02153632 |
| Other Study ID Numbers: |
OS320-3006 |
| First Posted: | June 3, 2014 Key Record Dates |
| Results First Posted: | April 2, 2019 |
| Last Update Posted: | April 12, 2019 |
| Last Verified: | April 2019 |
Keywords provided by Osmotica Pharmaceutical US LLC:
|
Parkinson's Disease Levodopa Induced Dyskinesia (LID) LID Parkinsonism Dyskinesia |
Additional relevant MeSH terms:
|
Parkinson Disease Dyskinesias Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases Neurologic Manifestations Amantadine Antiparkinson Agents |
Anti-Dyskinesia Agents Antiviral Agents Anti-Infective Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |